Sacituzumab govitecan plus pembrolizumab improves PFS across biomarker subgroups in metastatic triple-negative breast cancer
Sacituzumab govitecan plus pembrolizumab improves PFS across biomarker subgroups in metastatic triple-negative breast cancer
1: Safe administration and dosing of EGFR inhibitors in NSCLC - Practical guidance for oncology nurses
Personalised mRNA vaccine plus pembrolizumab shows durable benefit in high-risk melanoma
ASCO 2026: Highlights and analysis
Velzatinib demonstrates broad activity across KIT mutations in advanced gastrointestinal stromal tumours
Optimal panitumumab–bevacizumab sequencing evaluated in RAS wild-type metastatic colorectal cancer
Relacorilant chemo combination extends OS in platinum-resistant ovarian cancer
Aspirin in stage III colorectal cancer shows no significant DFS benefit but favourable safety
Short-term fasting linked to improved chemo response in advanced ovarian cancer
ASCO 2026: Latest in prostate cancer
Amivantamab in HPV-unrelated mHNSCC gives high response rates after immunotherapy and chemo
Gene expression test guided therapy in ER+/HER2- early breast cancer allows safe chemotherapy omission